Valdez MA, Arenas GR

Language: Spanish
References: 17
Page: 273-278
PDF size: 210.62 Kb.

ABSTRACT

Superficial mycoses are fungal infections that affect the externa layers of the skin, including hair and nails, and are caused by dermatophytes, yeasts, and non-dermatophyte molds.
Managing superficial mycoses is mandatory for dermatologists and gps. Regarding amorolfine, a morpholine derivative, inhibits ergosterol biosynthesis and provides effectiveness and safety in the treatment of ringworm and onychomycosis.
We performed a literature review about the chemical profile of amorolfine, clinical applications, efficacy, and market availability. Amorolfine remains a valuable tool in treating superficial mycoses, offering flexibility and effectiveness in monotherapy or combination with systemic treatments. Its proper application can optimize results and improve the quality of life of treated patients.

REFERENCES

1. Arenas R y Torres E, Micología médica ilustrada, 6ª ed., México,McGraw-Hill, 2019, pp. 69-113.

2. Feng X, Xiong X y Ran Y, Efficacy and tolerability of amorolfine5% nail lacquer in combination with systemic antifungal agentsfor onychomycosis: a meta-analysis and systematic review, DermatolTher 2017; 30. doi: 10.1111/dth.12457.

3. Gupta AK, Daigle D y Foley KA, Topical therapy for toenail onychomycosis:an evidence-based review, Am J Clin Dermatol2014; 15(6):489-502. doi: 10.1007/s40257-014-0096-2.

4. Haria M y Bryson HM, Amorolfine: a review of its pharmacologicalproperties and therapeutic potential in the treatment ofonychomycosis and other superficial fungal infections, Drugs1995; 49(1):103-20. doi: 10.2165/00003495-199549010-00009.

5. Del Palacio A, Gip L, Bergstraesser M y Zaug M. Dose-findingstudy of amorolfine cream (0.125%, 0.25% and 0.5%) in the treatmentof dermatomycoses, Clin Exp Dermatol 1992; 17(Suppl 1):50-5.

6. Bag G, Mubashir S, Sen D y Jadhwar S, Place in therapy of topicalamorolfine in the management of onychomycosis and tineapedis: a survey to understand Indian dermatologists’ perspective,ip Indian J Clin Exp Dermatol 2024; 10(2):149-54.

7. Arreaza F, González L, Moraleda I, Plaza M y Yépez E, Uso dela amorolfina tópica en forma de laca en pacientes con onicomicosispor hongos oportunistas (mohos y levaduras). Estudiomulticéntrico abierto, Dermatol Venez 2006; 44(4).

8. Franz TJ, Absorption of amorolfine through human nail, Dermatology1992; 184(Suppl 1):18-20.

9. Roncari G, Ponelle CH, Zumbrunnen R, Guenzi A, DingemanseJ y Jonkman JHG, Percutaneous absorption of amorolfine followinga single topical application of an amorolfine cream formulation,Clin Exp Dermatol 1992; 17(Suppl 1):33-6.

10. Polak A, Kinetics of amorolfine in human nails, Mycoses 1993;36:101-3.

11. Polak A, Preclinical data and mode of action of amorolfine, Dermatology1992; 184(Suppl 1):3-7.

12. Chen S, Ran YP, Dai YL, Lama J y Hu WY, Case of infantile onychomycosissuccessfully cured by 5% amorolfine nail lacquer, JPediatr Child Health 2014; 50:933-4.

13. Pittrof F, Gerhards J, Erni W y Klecak G, Loceryl® nail lacquer:realization of a new galenical approach to onychomycosis therapy,Clin Exp Dermatol 1992; 17(Suppl 1):26-8.

14. Tabara K, Szewczyk AE, Bienias W, Wojciechowska A, PastuszkaM, Oszukowska M y Kaszuba A, Amorolfine vs. ciclopirox: lacquersfor the treatment of onychomycosis, Derm Alergol 2015;32(1):40-5. doi: 10.5114/pdia.2014.40968.

15. Zhang J, Lu S, Huang H, Li X, Cai W, Ma J y Xi L, Combinationtherapy for onychomycosis using a fractional 2940-nm yag laserand 5% amorolfine lacquer, Lasers Med Sci 2016; 31:1391-6.doi: 10.1007/s10103-016-1990-z.

16. Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H, KerroucheN y Sidou F, Application of cosmetic nail varnish does not affectthe antifungal efficacy of amorolfine 5% nail lacquer in the treatmentof distal subungual toenail onychomycosis: results of arandomised active-controlled study and in vitro assays 2016;59:319-26.

17. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N ySidou F, Efficacy of amorolfine nail lacquer for the prophylaxisof onychomycosis over 3 years, J Eur Acad Dermatol Venereol2010; 24:910-5.